We have previously shown that interleukin (IL)-2 receptor-expressing lymphoid cells stimulated with a chimeric protein linking IL-2 to the ectodomain of TGF-b receptor II (also known as FIST) become resistant to TGF-b-mediated suppression and produce significant amounts of proinflammatory cytokines. In this study, we have characterized the antigen presentation properties of FIST-stimulated B cells (hereafter inducible B effector cells, iBEC). FIST converts na€ ve splenic B cells to B effector cells characterized by potent antigen presentation properties and production of TNFa and IFNg. iBECs display hyperphosphorylation of STAT3 and STAT5 downstream of the IL-2 receptor and upregulation of T-bet expression. iBECs maintain B-cell identity based on the expression of PAX5 and CD19 and overexpress Smad7, which confers resistance to TGF-b-mediated suppression of B-cell activation. iBEC antitumor immunity was determined by a mouse model of lymphomaexpressing ovalbumin (E.G7-OVA) as a specific tumor antigen. OVA-pulsed iBECs function as antigen-presenting cells (APC) in vitro by inducing the activation of OVA-specific CD4 þ and CD8 þ T cells, respectively, and in vivo by conferring complete protective immunity against E.G7-OVA tumor challenge. In addition, OVA-pulsed iBECs promote tumor regression in immunocompetent C57Bl/6 mice bearing E.G7-OVA tumors. In conclusion, iBECs represent an entirely novel B cell-derived APC for immune therapy of cancer. Cancer Res; 72(5);
Introduction
Antigen presentation is required for the development of effective cell-mediated immunity (1) . Dendritic cells (DC) have been extensively used as cellular adjuvants to present antigen in vivo (2, 3) . Although highly effective in their ability to induce T cell-mediated immunity, the clinical applicability of DCs has encountered several disadvantages. First, they are relatively rare in peripheral blood (<1% of leukocytes) and are therefore usually isolated from leukapheresis or marrow sources (4) . Second, they are comprised by a heterogeneous population with distinctive functions and third, they are difficult to expand in vitro from a nonstem cell source (5) . As an alternative source of antigen-presenting cells (APC), B cells are reliably expandable from nonstem cell source with small amounts of peripheral blood.
A new B-cell classification takes into account: (i) the pattern of polarized cytokines produced by B cells, (ii) the cytokine environment in which they were stimulated during their primary encounter with antigens, and (iii) the T-cell subsets they interact with. Two effector B-cell subsets have been identified based on this classification system. The B cell stimulated by T H 1 effectors were coined B effector 1 (Be1) cells and B cells stimulated by T H 2 effectors are known as B effector 2 (Be2) cells (6) . Be1 cells mainly produce T H 1 cytokines [IFNg and interleukin (IL)-12], whereas Be2 produce T H 2 cytokines (IL-4 and IL-5). The combination of antigen stimulation and interaction with polarized effector T H 1 and T H 2 cells dictate the differentiation of na€ ve B cells toward IFNg or IL-4-producing cells capable of triggering a T H 1 or T H 2 differentiation program in na€ ve T cells, respectively (6, 7) .
Like DCs, B cells can process and present antigens in the context of MHC class II molecules and recruit specific CD4 þ T cell help, which in turns stimulates B-cell proliferation and differentiation (8, 9) . In addition, B cells express high levels of MHC class I and therefore act as APC for CD8 þ T cells, which stimulates IL-2 production and cytotoxic T cells (CTL) activity (10, 11) . It has also been shown that B cell-derived APCs are comparable with mature DCs in regards to presentation function in vivo (12) . However, the method required to convert and expand na€ ve B cells to APCs requires coculture with CD40L-expressing transfected cell lines or coculture with T-helper cells (13) , which may represent a substantial logistical and regulatory obstacle to clinical translation of B cell-derived APCs in first-in-human use for immunotherapy purposes.
Here, we describe an entirely novel remedy to this conundrum which will allow further development of B cell-derived APCs as a distinct APC for immunotherapy.
We have previously shown that molecular genetic engineering of a fusion protein linking IL-2 to a TGF-b decoy receptor (14) adopts a hybrid IL-2-like cytokine function characterized by inhibition of TGF-b signaling and hyperactivation of IL-2 signaling via STAT1. Here, we show that na€ ve spleen-derived B cells stimulated in vitro with FIST undergo a massive mitogenic response and adopt an entirely novel APC phenotype and functional profile distinct from that previously described for Be1-, Be2-, and CD40L-activated B cells. We further show that these FIST-inducible B effector cells (iBEC) can lead to antigenspecific antitumor activity and immune protection against tumor challenge in vivo.
Materials and Methods

Mice, reagents, and antibodies
All experimental C57BL/6, transgenic mice (OT1 and OT2) and knockout mice (CD4 þ and CD8 þ T cell) were females of 6 to 8 weeks old (Jackson Laboratory). Antiphosphorylated and total length STAT3, STAT5, STAT1, BCL6, and BLIMP-1 antibodies were obtained from Cell Signalling Technology; b-tubulin and SMAD7 antibodies were obtained from Santa Cruz Biotechnology. Anti-mouse FcR III/II, CD79b (BCR subunit),  T-bet, IFNg, IL-4, IL-17, MHC class I and II, CD19, CD4, CD45R  (B220), CD24, CD22.2, CD43, CD279, CD138, CD27, CD80, CD86,  CD25, CD69, CD23, CCR7, FasL, TRAIL, CD95 , and CD40 and the isotype control antibodies for flow cytometry were obtained from BD Biosciences.
B-cell isolation, generation, and phenotypic analysis of FIST-stimulated B cells B cells were isolated from splenocytes of immunocompetent C57BL/6 by magnetic separation with the EasySep Mouse B Cell Isolation Kit (Stemcell Technologies) according to the manufacturer's recommendations. B-cell population purity assessed by flow cytometry was 96%. FIST or control-stimulated B cells were generated by culturing B cells with 2 pmols per milliliter of FIST or controls (IL-2, sTbRII, and IL-2 plus sTbRII) for 3 to 4 days at 37 C. FIST and control protein were obtained as previously described (14) . For cell surface marker staining, iBECs were resuspended in PBS with 2% FBS, incubated with anti-human FcR III/II for 30 minutes and labeled with conjugated antibodies specific for CD79b (BCR subunit),  MHC class I and II, CD19, CD45R (B220), CD24, CD22.2, CD43,  CD279, CD138, CD27, CD80, CD86, CD25, CD69, CD23, CD95,  CCR7 The data were analyzed by Cellquest software (Becton Dickinson).
In vivo experiments
In a prophylactic setting, 1 Â 10 5 OVA-pulsed iBEC or control-stimulated B cells were subcutaneously injected into C57BL/6 immunocompetent mice, and 3 weeks later mice were boosted with 4 Â 10 5 OVA-pulsed iBEC or control-stimulated B cells. One week after the second boost, mice were challenged with 5 Â 10 5 E.G7 tumor cells. Similar experiments were repeated with CD4 þ and CD8 þ T cells knockout mice. Tumor volume and percentage of survival were determined over time.
In a therapeutic setting, 5 Â 10 5 E.G7 tumor cells were subcutaneously implanted into C57BL/6 immunocompetent mice and once mice developed palpable tumors, they were treated with 2 doses of 3 Â 10 6 OVA-pulsed iBEC or controlstimulated B cells. Tumor volume and percentage of survival were determined over time.
Statistical analysis
We used the 2-tailed unpaired Student t test to compare 2 experimental groups, the Dunnett multiple comparisons to compare 3 or more test groups.
Results
FIST induces B-cell activation and differentiation to an APC effector phenotype B cells cultured with FIST for 3 to 4 days undergo a differentiation process characterized by phenotypic changes including an increase in size and granularity defined by side scattergram profile (SSC) and forward scattergram profile (FSC; Fig. 1A ) and hematoxylin and eosin staining (Fig. 1B) . In addition, iBECs display a significant mitogenic response compared with IL2-stimulated B cells in vitro (Fig. 1C) . sTbRII by itself or in combination with IL-2 does not induce B-cell proliferation ( Supplementary Fig. S1A ). To characterize the phenotype of FIST-expanded cells (iBEC), we measured the expression levels of several B-cell receptors and costimulatory molecules including CD79b (BCR subunit), MHC class I and II, CD19, CD45R (B220), CD24, CD22.2, CD43, CD138, CD27, CD80, CD86, CD25, CD69, CD23, CD95, CCR7, FasL, and CD40. In comparison with control-stimulated B cells (2 pmols/mL of IL-2, sTbRII or IL2 plus sTbRII), iBEC upregulate costimulatory molecules (CD86), markers of activation (CD69), B-cell memory marker (CD27), B-cell identity markers CD45R (B220) and CD19, IL-2 receptor alpha subunit (CD25), as well as MHC class I and II expression (Fig. 1D ). In addition, iBECs display significantly higher migration to the lymph nodes than resting B cells but similar migration as control-activated B cells (IL-2, sTbRII, and IL-2 combined with sTbRII; Supplementary Fig. S1B ).
FIST induces B-cell activation via Janus-activated kinase/STAT signaling pathway and Smad7 expression iBECs and B cells stimulated by equimolar concentrations of IL-2 combined with sTbRII for 30 minutes show similar activation levels of STAT3 and STAT5 (data not shown), and no STAT1 phosphorylation was detected (data not shown). In contrast, iBECs in culture for 3 days display a distinctive hyperactivation of both STAT3 and STAT5 ( Fig. 2A) . Pax5 is highly expressed in all the conditions tested whether with iBEC or control-stimulated B cells. As previously observed for CTLL-2 and splenocytes (14) , FIST also upregulates SMAD7 expression in B cells. Paradoxically, iBECs display a robust upregulation of BLIMP1 expression combined with BCL6 downregulation (Fig. 2B ) in the absence of the plasma cell marker CD138 (data not shown).
FIST imprints a Be1-like phenotype
To interrogate whether FIST promotes a Be1-like phenotype, T-bet expression and IFNg secretion were measured over time in B cells (from immunocompetent mice and STAT1 knockout mice) cultured with FIST. FIST induces a significant increase in T-bet expression and IFNg production by both B cells from immunocompetent mice (Fig. 3A and B) and STAT1 knockout mice ( Supplementary Fig. S2A ). IFNg expression by CD19-positive cells was verified by intracellular staining with IFNgspecific conjugated antibodies ( Supplementary Fig. S2B ). In addition, iBECs secrete high levels of proinflammatory cytokines (GM-CSF, TNFa, and IL-6; Fig. 3C and D) and no detectable levels of IL-5, IL-15, and IL-12 measured by ELISA (data not shown). There was no detectable IL-4 and IL-17 by intracellular cytokine staining of CD19-or B220-positive cells ( Fig. 3E and F) .
iBECs promote T-cell activation and polarization OT1 and OT2 T cells were designed to recognize OVA 257 to 264 residues in the context of H2K b or 323 to 339 residues in the context of I-A b , respectively. iBECs only induce OT2 CD4 þ T-cell activation when they were previously pulsed with OVA antigens, whereas no IL-2 or IFNg was detected in the absence of OVA loading ( Supplementary Fig. S3A and S3B ). OVA-pulsed iBECs promote significantly greater CD4 þ and CD8 þ T-cell activation and T H 1 cytokine (IL-2 and IFNg) production than OVA-pulsed B cells previously stimulated with equimolar concentration of cytokine controls ( Fig. 4A and B) . To characterize the type of T helper-mediated immunity induced by iBECs, OT2 CD4 þ T cells were cocultured with OVA-pulsed (Fig. 4C ). Both OVAspecific CD4 þ and CD8 þ T cells proliferate in vitro in response to OVA presented by iBECs (Fig. 4D ).
iBECs as effector and inducer of CTL activity and NK cell activation iBECs upregulate TRAIL expression (Fig. 5A ), but they do not display significant in vitro cytotoxic activity against either a DR5-null (EG7) or a DR5 þ (TUBO) tumor cell line (data not shown). In contrast, iBECs promote CTL activity in OT1 CD8 þ T cells in an antigen-dependent manner. CTL cells induced by iBECs display significant cytotoxicity (55% versus no killing by control-stimulated cells) against E.G7 tumor cells (Fig. 5B ). In addition, iBECs induce NK cell activation based on the expression of CD69 (Fig. 5C ). Activated NK cells display an increase in size and granularity defined by SSC and FSC (Fig. 5D ).
OVA-pulsed iBEC induce protective immunity against OVA-expressing tumor challenge OVA-pulsed iBEC conferred complete protection to mice from E.G7-OVA tumor challenge. In contrast, the majority (60%-80%) of mice previously treated with nonstimulated or control-stimulated and OVA-pulsed B cells developed tumors and were sacrificed (Fig. 6A, B, and C) . To characterize the antigen presentation properties of OVA-pulsed iBECs in vivo, similar experiments were carried out in CD4 þ and CD8 þ T cell knockout mice. Although both strains developed tumors, indicating that OVA-pulsed iBECs failed to induce protective antitumor immunity, tumor grew faster in CD4 þ T cell knockout mice. Consequently, CD4 þ T cell knockout mice display a percentage of survival similar to control groups ( Fig. 6D and E) . On the contrary, in CD8 þ T cell knockout mice, the tumors grew with significant delay compared with the control group and 20% of the mice display protective immunity against tumor challenge ( Fig. 6F and G) . Nine weeks after tumor implantation, treated mice sera were collected to quantify OVA-specific antibody titer by ELISA. No significant differences were observed in the level of OVA-specific antibodies obtained from mice treated with OVA-pulsed iBECs and IL-2 plus sTbRII-stimulated B cells (Supplementary Fig. S4 ).
OVA-pulsed iBEC treatment significantly inhibits tumor growth C57BL/6 mice with preestablished tumors (previously injected with 5 Â 10 5 E.G7-OVA tumor cells) were treated with OVA-pulsed iBECs or control-stimulated B cells. Two intravenous injections of 3 Â 10 6 B cells were given a week apart and tumor volume was determined over time (Fig. 7A) . Mice bearing palpable tumors (previously implanted with 5 Â 10 5 E.G7 cells) and treated with OVA-pulsed B cells developed tumors that progressed in a similar manner to the nontreated control group (Fig. 7B and C) . In contrast, mice treated with OVA-pulsed iBECs displayed a delay of tumor growth and 20% of treated mice showed complete tumor rejection (Fig. 7D) , which remained tumor free for a period of 7 months (data not shown). Overall, mice treated with OVA-pulsed iBECs displayed significant lower rate of tumor growth over time (Fig. 7E) . Consequently, FIST converts na€ ve B cells to a new type of Bcell effector characterized by the appearance of phenotypic and functional features distinct from Be1 or Be2 cells as previously described. A dramatic upregulation of CD25, activation marker (CD69), costimulatory molecule (CD86), and MHC class (I and II) molecule expression are indicative of B-cell responsiveness to FIST stimulatory effects. iBECs increase in size and granularity, but they do not differentiate into plasma cells because they keep their B-cell identity based on CD19 and B220 expression, proliferate, and express high levels of MHC class II molecules; features that typically disappear once B cells are fully differentiated into plasma cells (15, 16) . STAT3 and STAT5 activation in B cells play opposite roles in the regulation of B-cell fate. Specifically, STAT3 activation upregulates BLIMP1 gene expression promoting plasma cell differentiation, while downregulating BCL6 expression (17) . In contrast, STAT5 activation leads to self-renewal and inhibition of plasma B-cell differentiation due to upregulation of BCL6 expression (15, 18) . Interestingly, iBECs display hyperactivation of both STAT3 and STAT5, the sum of whose effects are downregulation of BCL6 expression coordinated with a robust BLIMP1 upregulation that paradoxically coexists with high levels of Pax5 and MHC class II expression in proliferating cells. Therefore, despite STAT3 activation, iBECs do not acquire a plasma cell phenotype.
Furthermore, FIST-mediated STAT5 activation may be partially antagonized by FIST-mediated STAT3 activation because STAT5 activation fails to inhibit STAT3-dependent BLIMP1 upregulation and BCL-6 downregulation. Notwithstanding (14) . TGF-b increases the rate of apoptosis of normal resting B cells via caspase 3 (19) and inhibits CIITA and MHC class II expression (20) . FIST-mediated STAT3 activation may also induce Smad7 expression which directly inhibits the TGF-b pathway in iBECs (21) (22) (23) . Therefore, iBECs are also resistant to TGF-b-dependent suppression of activation. This functional TGF-b signaling blockade in combination with potent Janusactivated kinase (JAK)/STAT activation induces iBECs to produce significant quantities of IFNg, which correlate with progressive induction of the master regulator of IFNg gene transcription, T-bet. Previous reports indicate that T-bet and IFNgR expression are required for IFNg production by Be1 cells. In contrast to T cells, IFNg production in Be1 cells is not critically dependent on STAT1 coupled to IFNgR (24) . In accordance with previous reports, iBECs from STAT1 knockout mice produce similar amounts of IFNg as iBEC from normal mice. This confirms that IFNg production in B cells is regulated by a STAT1-independent mechanism and suggests that other transcription factors or STAT proteins such as STAT3 may act as transducers of IFNgR signaling in B cells.
As observed in Be1 cells (6) , iBEC produce IFNg, TNFa, and IL-6, but not IL-4, IL12, or IL-17. Similarly to Be1-and CD40-activated B cells, iBECs pulsed with antigens are able to polarize na€ ve T cells into T H 1 cells, as well as promote the generation of antigen-specific CTL.
Although iBECs exhibit similar migration capacity to the lymph nodes as control-activated B cells, they promote more potent activation and proliferation of CD4 þ and CD8 þ T cells in an antigen-dependent manner, as observed in vitro. In addition, iBECs promote polarization of T cells into T H 1-like cells that produce high levels of T H 1 polarized cytokines such as IFNg and IL-2 as well as CTL activity against tumor cells expressing T cell-specific antigens. Furthermore, iBECs induce the activation of NK cells, which display features characteristic of differentiated lymphokineactivated killer cells such as an increase in size and granularity. In addition, iBECs display upregulation of TRAIL expression, which suggest that they may directly act as effector cells by inducing apoptosis of susceptible cells through TRAIL receptor engagement (25) . However, we found that iBECs do not display significant in vitro cytotoxic activity against either a DR5 À null (EG7) or a DR5 þ (TUBO) tumor cell lines. The sum of these data suggest that TRAIL and IFNg production by iBECs may be insufficient on their own to mediate direct cytolysis of tumor cells expressing (or not) DR5.
In a cancer vaccine setting, OVA-pulsed iBECs confer complete protective immunity against tumor cells expressing specific OVA antigen. Because tumor growth rates from both OVA-pulsed iBEC and control groups are similar in CD4 þ T cell knockout mice, we conclude that the potent protective immunity observed in immunocompetent mice requires help from antigen-specific CD4 þ T cells primed by OVA-pulsed iBECs. Although, the OVA-pulsed iBEC-treated group developed tumors in CD8 þ T cell knockout mice, their tumors grew with a significant delay compared with the nontreated group and 20% of treated mice displayed protective immunity. These results indicate that, besides CD8 þ T cells, other immune effectors may also contribute to the antitumor response observed in vivo. Indeed, iBECs also induce NK cell activation, which may occur by a cell contact-dependent mechanism via costimulatory molecule interactions or by the production of proinflammatory cytokines by iBECs (26, 27) . The use of FIST as a tool to generate and expand Be1-like cells with potent antigen-presenting properties, cytokine and chemokine production circumvent the requirement of T H 1 polarized cells, transfected feeder cells, and cytokines needed to differentiate B cells into Be1 cells. Furthermore, this is the first in vivo study that shows the effectiveness of ex vivo activated B cells to induce antitumor protective immunity. In conclusion, iBECs display a novel B effector phenotype and act as potent APCs that protect mice from tumor challenge in an antigen-dependent fashion. Therefore, FIST could serve as a tool for ex vivo B-cell expansion and activation for the cell-based therapy of cancer.
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